Key statistics
On Monday, Summit Therapeutics Inc (SMMT:NMQ) closed at 16.19, 17.06% above the 52 week low of 13.83 set on Feb 05, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 16.00 |
|---|---|
| High | 16.41 |
| Low | 15.85 |
| Bid | 15.70 |
| Offer | 16.18 |
| Previous close | 16.59 |
| Average volume | 1.89m |
|---|---|
| Shares outstanding | 775.37m |
| Free float | 134.76m |
| P/E (TTM) | -- |
| Market cap | 12.55bn USD |
| EPS (TTM) | -1.44 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Summit Therapeutics to Present at Upcoming Investor Conferences
- Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
- Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
- Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
- Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼
